Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04158687 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
A Phase 2 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 326
- Enrollment target
NCT04158687: Completed Phase 2 study, sponsored by Concert Pharmaceuticals.
NCT04158687 is a Phase 2 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 326 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (145% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04158687, a Phase 2 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 326 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily (QD) for 12 weeks to adult participants with schizophrenia on stable dopaminergic antipsychotic medication.
Primary Outcome
PANSS measures symptom severity in participants with schizophrenia. PANSS includes 30 items (7 items for positive symptoms, 7 items for negative symptoms, and 16 items for general psychopathology symptoms), and each item is rated with 1 to 7 points. The PANSS is scored by summation of ratings across items such that the score ranges are 7 to 49 for each of the Positive and Negative Scales and 16 to 112 for the General Psychopathology Scale. The PANSS total score is a sum of scores from all the 30
Interventions
- DRUG Placebo
- DRUG CTP-692
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2019-11-26 |
| Est. Completion | 2020-12-22 |
| Phase | Phase 2 |
What the finished NCT04158687 record still lists
NCT04158687 is an interventional study that assigns participants to a tested intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (145% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04158687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04158687 about?
NCT04158687 is a clinical study titled "A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia". The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily (QD) for 12 weeks to adult participants with schizophrenia on stable dopaminergic antipsychotic medication.
What is the current status of trial NCT04158687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 326 participants. The study started on 2019-11-26. Estimated completion is 2020-12-22.
What interventions are being tested in trial NCT04158687?
The interventions under investigation include: Placebo (DRUG), CTP-692 (DRUG).
Who is sponsoring clinical trial NCT04158687?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04158687's enrollment target sits among peer trials
326 147th of 2000 higher than 1,853 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06410144 · 326 participants · NA
Chronic Kidney Disease-Education (CKD-EDU)
- NCT06586619 · 326 participants · NA
A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV
- NCT07040566 · 326 participants · Phase 2
A Trial of Varenicline for E-cigarette Cessation
- NCT07165860 · 326 participants · NA
Clinical Trial to Reduce Perinatal Intimate Partner Violence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI